SCHEMBL24460341

SCHEMBL24460341

O=C(N1CCNCC1)N1CCSc2cc(C(F)(F)F)ccc2C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RYR2 Q92736 9/20 0.57
KCNH2 Q12809 3/20 0.39
ABHD6 Q9BV23 1/20 0.38
DPP4 P27487 1/20 0.38
SCN7A Q01118 1/20 0.37
SCN9A Q15858 1/20 0.37
HTR2C P28335 2/20 0.37
MAOB P27338 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2B P41595 1/20 0.37
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HTR1D P28221 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
AKR1C3 P42330 1/20 0.36
DPP7 Q9UHL4 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29563422 1.00 RYR2 (0.57) RYR2KCNH2ABHD6DPP4SCN7A
Hydrochloric Acid SCHEMBL29563405 0.99 RYR2 (0.56) RYR2KCNH2ABHD6DPP4SCN7A
SCHEMBL29563318 0.92 RYR2 (0.65) RYR2KCNH2
SCHEMBL24460327 0.92 RYR2 (0.65) RYR2KCNH2
Hydrochloric Acid SCHEMBL29563284 0.91 RYR2 (0.64) RYR2KCNH2
SCHEMBL26942211 0.88 RYR2 (0.64) RYR2KCNH2DPP4ALDH1A1AKR1C3
SCHEMBL24460318 0.83 RYR2 (0.60) RYR2KCNH2
SCHEMBL26942239 0.83 RYR2 (0.63) RYR2KCNH2
SCHEMBL24460462 0.81 RYR2 (0.45) RYR2DPP4DPP7
SCHEMBL29563475 0.81 RYR2 (0.45) RYR2DPP4DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399324-A1 AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS RYCARMA THERAPEUTICS, INC. 2023-12-14 US disclosed
WO-2022108945-A1 AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS ARMGO PHARMA, INC. (US) 2022-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399324-A1 AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS RYR2, RYR1, ATP2A1 RYR2 1/4885KCNH2 605/4885ABHD6 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.